Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121. KPI-121 achieved statistical significance for the primary sign endpoint of bulbar conjunctival hyperemia, and promising trends were observed for key symptom endpoints. “The achievement of statistical significance for the primary sign endpoint in this relatively small trial is an extremely important accomplishment,” said Kim Brazzell, PhD, Chief Medical Officer of Kala.
Read the entire article here
Preclinical Ophthalmic Contract Research